Emalex Biosciences

Emalex Biosciences is a biopharmaceutical company dedicated to developing new therapies for rare and orphan neurological diseases. Ecopipam (EBS-101), its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette syndrome and stuttering.